Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy.
Principal investigators Dr. Aaron Nagiel, MD, PhD, at Children’s Hospital of Los Angeles, and Dr. Lesley Everett, MD, PhD, MPhil, at the Oregon Health Sciences… Read More »Clinical researchers on X-linked retinoschisis (XLRS) reports the dosing of a first patient in a phase 1 / 2 study.
Researchers at the Department of Ophthalmology, University of California, Irvine and the Structural Biology Research Centre, Vrije Universiteit Brussels, Belgium, have reported the use of… Read More »US & Belgium research team discover a novel “nanobody” (a “mini-antibody”) potentially applicable to retinitis pigmentosa (RP) treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 14th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »September 14th, 2023 “EURETINA-Brief”© Issue No. 278
